[1] |
Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050?[J]. Int J Cancer, 2021, 148: 1051-1065.
|
[2] |
Steele CD, Abbasi A, Islam SMA, et al. Signatures of copy number alterations in human cancer[J]. Nature, 2022, 606: 984-991.
|
[3] |
Shlien A, Malkin D. Copy number variations and cancer[J]. Genome Med, 2009, 1: 62.doi:10.1186/gm62.
|
[4] |
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4: 44-57.
|
[5] |
Shen W, Song Z, Zhong X, et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform[J]. iMeta, 2022, 1: e36.doi:10.1002/imt2.36.
|
[6] |
Szklarczyk D, Gable A L, Nastou K C, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res, 2021, 49: D605-D612.
|
[7] |
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45: W98-W102.
|
[8] |
Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12: 31-46.
|
[9] |
Pelaz SG, Tabernero A. Src: coordinating metabolism in cancer[J]. Oncogene, 2022, 41: 4917-4928.
|
[10] |
Yang J, Zhang X, Liu L, et al. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway[J]. Life Sci, 2021, 264: 118711. doi: 10.1016/j.lfs.2020.118711.
|
[11] |
Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy[J]. Cells, 2020, 9: 198. doi: 10.3390/cells9010198.
|
[12] |
Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy[J]. World J Hepatol, 2015, 7: 1964-1970.
|
[13] |
Huang Z, Tang B, Yang Y, et al. MAP3K7-IKK inflam-matory signaling modulates AR protein degradation and prostate cancer progression[J]. Cancer Res, 2021, 81: 4471-4484.
|